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1. ABSTRACT 
 
Aging is a complex process that negatively 
impacts the development of the different systems and its 
ability to function.  Moreover, the Aging rate in humans is 
not the same, principally due to genetic heterogeneity and 
environmental factors. The aging rate is measured as the 
decline of functional capacity and stress resistance. 
Therefore, several attempts have been made to analyse the 
individual age, ( so-called biological age) compared to 
chronological age. The biomarkers of aging are age-related 
body function or composition, these markers aim to assess 
the biological age and predict the onset of age-related 
diseases and/or residual lifetime. Such biomarkers should 
help in one hand to characterise the biological age and on 
the other hand to identify individuals at high risk of 
developing age-associated diseases or disabilities. 
Unfortunately, most of the markers under discussion are 
related to age-related diseases rather than to age, so none of 
these markers discussed in literature is a true biomarker of 
aging. Hence, we discuss some disease-related biomarkers 
useful for a better understanding of aging and the 
development of new strategies to counteract it, essential for 
improving the quality of life of the elderly population.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2. INTRODUCTION 
 
Aging results from a breakdown of self 
organizing system and reduced ability to adapt to 
environment. In addition, it has been suggested that normal 
human Aging is associated with a loss of complexity in a 
variety of fractal-like anatomic structures and physiological 
processes (1). Furthermore, using a variety of measures that 
employ fractal analysis, Aging has been shown to be 
associated with a loss of complexity in blood pressure (2), 
respiratory cycle (3), stride interval (4), and postural sway 
dynamics (5). 
 
However, there is a judge difference among 
people that age: there are people at the age of 90 years old 
still in good mental and physical condition and other that at 
60 years old have extensive cognitive difficulties and 
chronic diseases. Overall, understanding Aging  means 
being able to quantify physical inability, mental functional 
capacity, organs and apparatus deregulation (6).  
 
Aging is considered a process that changes the 
performances of most physiological systems and increases 
susceptibility to diseases and death. The Aging phenotype 
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is a complex interaction of stochastic, environmental, 
genetic and epigenetic variables. However, these variables 
do not create the Aging phenotype but generate the lost of 
molecular fidelity and therefore as the random 
accumulation of damage in the human organism's cells, 
tissues, or whole organism during life increases,  the 
probability of disease and death also augments in 
proportion (7).  
 
In the society, the public perception of advanced 
Aging involves the inability to survive due to chronic 
diseases and the combined loss of mobility, sensory 
functions, and cognition (8) with an exponential growth of 
health costs linked to increased size of elderly in the 
Western World. So, biomarkers of human Aging are 
urgently needed to assess health state of elderly and the 
possible therapeutic interventions. 
 
What a biomarker for Aging should be or predict is 
quite broadly defined. At the minimum, a biomarker should 
not only (i) reflect some basic property of Aging, but also (ii) 
be reproducible in cross-species comparison, (iii) change 
independently of the passage of chronological time (so that the 
biomarker indicates biological rather than chronological age), 
(iv) be obtainable by non invasive means, and (v) be 
measurable during a short interval of life span. A biomarker 
should reflect the underlying Aging process rather than disease 
(9). It should vary as an individual ages, but not strictly 
chronologically; instead, its quantity should correlate with 
remaining life span and with the likelihood of acquiring 
multiple age-related conditions. Furthermore, scientists will 
likely need a set of numerous biomarkers, perhaps some that 
provide a window on particular tissues and others that give a 
glimpse of an entire organism, to replace life span as the best 
measure of Aging.  
 
Another problem, which is even more challenging, 
is that unless we understand how Aging "works," we might not 
be able to define ideal biomarkers at all. A biomarker would 
have only limited utility without understanding of the 
biological complexity of the system and above all how we can 
influence the complexity of structure. Moreover, which tissues 
or organs are preferable to evaluate as a predictable marker?  
Maybe it can be taken from blood, urinary tract or central 
nervous system; biochemical markers are better suitable than 
histology markers that are still to find out. 
 
Unfortunately, most of the markers under discussion 
are related not only to age, but also to diseases, and thus none 
of the markers discussed in literature is a pure biomarker of 
Aging. A recent report has stated that biomarkers collected in 
physical exams, such as markers of cardiovascular diseases 
(CVD) and diabetes are useful predictors of healthy Aging 
(10). In the present review, we will discuss markers based on 
immunosenescence, inflammatory responses and oxidative 
stress. The review is based on data from author laboratories 
rather than on an extensive review of the literature. 
 
3. BIOMARKERS OF IMMUNOSENESCENCE  
 
The modifications of the immune system in the 
elderly are evaluated as a deterioration of the immune 
system, the so-called immunosenescence, which is thought 
to be mostly the result of the declining effectiveness of T 
cells. It contributes to higher morbidity and mortality 
caused by the increased susceptibility  to infectious 
diseases or their reactivation as well as to autoimmune 
phenomena and cancer (11-13). 
 
It is well established that the percentage and the 
number of naïve T cells is lower in the elderly than in the 
young. Age-associated thymic involution is thought to 
materially contribute to this phenomenon. Reciprocally, the 
percentage and numbers of memory and effector-memory 
cells are higher in the elderly. In fact, lifelong and chronic 
antigenic load results the major driving force of 
immunosenescence, which impacts on lifespan by reducing 
the number of virgin antigen-non experienced T cells, and 
filling the immunological space with expanded clones of 
memory and effector, antigen-experienced T cells. Thus, 
the repertoire of cells available to respond to antigenic 
challenge from previously unencountered pathogens is 
shrinking (11,14,15).  
 
Several studies have underlined the importance of 
ubiquitous viruses causing chronic latent infections, such as 
Herpes Viruses, in determining characteristic aspects of T-
cell branch senescence such as the progressive exhaustion 
of naïve lymphocytes, the increase in memory cells and the 
T repertoire shrinkage. Particularly, the Herpes virus 
Cytomegalovirus (CMV) seropositivity has been associated 
with many of the same phenotypic and functional alterations of 
T-cell immunity previously considered as Aging biomarkers.  
CMV-specific lymphocytes represent, even in 
immunocompetent subjects, a sizable proportion of both the 
CD8+ and the CD4+ memory compartment and they increase 
with age, with a significant increase in the proportions of 
highly differentiated effector memory and effector CD45RA+ 
CD8 T cells in comparison to younger subjects. Furthermore, 
the increase of these cells is due to the expansion of terminally 
differentiated exhausted lymphocytes and expanded clones 
restricted towards specific epitopes, with  the accumulation of 
large oligoclonal expansions of CD8+ T cells (16-20).  
 
Thus, the analysis of T cells in longitudinal 
studies in octogenarians and nonagenarians has defined an 
“immune risk phenotype” (IRP), originally characterized 
by an inverted CD4/CD8 ratio and low lymphoproliferative 
response, that constitutes a major predictor of no survival. 
In addition, very old subjects with a health status impaired 
by the most common age-related diseases exhibit an 
increase in CMV-specific effectors T cells, mostly CD4+, 
with a parallel increase in anti-CMV IgG antibodies.  As 
previously stated,  persistent CMV infection induces 
chronic stimulation of specific T cells that leads to terminal 
differentiation to senescent cells with an altered functional 
capability. Thus,  elderly  have high expansions of CMV 
specific CD8 T cells that display an effector memory 
phenotype characterized by the low expression of CD28 
and increased expression of NK-associated receptors. 
Therefore, a critical indicator of incipient mortality is T cell 
repertoire attrition. Furthermore, several studies have 
suggested a positive association between in vitro T cell 
function and individual longevity (17, 21-29). 
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Also in the B compartment age-dependent 
changes indicate that advanced age is characterized by lack 
of B instructive immune response to new extracellular 
pathogens. B cell number is decreased and the B-cell 
repertoire is influenced by Aging through the quality of the 
antibody response. Changes in B cell repertoire have been 
described, and decreased B cell diversity in old age is 
correlated with poor health status. In addition, decreased 
IgM and IgD levels in elderly suggest a shift from the naïve 
(CD27-) compartment of the B cell branch towards the 
memory (CD27+) compartment. However, data are 
controversial since not all studies have shown, in elderly,  a 
significant decrease of naïve CD27- B cells and an increase 
of CD27+ memory B cells (30-35).  
 
Circulating B cells can be divided on the basis of 
the expression of IgD and CD27 into different functional 
subsets. In aged, a double-negative (DN) IgD-CD27- B cell 
subset is significantly increased. The origin of DN cells is 
not well understood as they might derive from activated 
CD27+ memory cells that have lost CD27 expression (32, 
36-38). Hence, they might be similar to the effector T 
exhausted T cells, previously stated. 
 
Of interest, B naïve lymphocytes are increased in  
offspring of healthy centenarians. It is well known that 
centenarian offspring, who are in their 70s and 80s, have a 
survival advantage when compared with control subject of 
the same age range whose parents died at an average life 
expectancy (39). The main lymphocyte differences 
observed between the two groups concern B cells. Indeed 
naïve B cells are more abundant as well as double negative 
B cells are less abundant in centenarian offspring. These 
data are similar to that found in previously experiment on 
young subjects. So, B cell compartment of the offspring of 
centenarians seems to be more similar to that of young 
respect to the old one (40). 
 
However, the age-dependent B cell changes here 
briefly discussed indicate that the loss of naive B cells 
could represent a hallmark of immunosenescence and could 
provide a biomarker possibly related to the life span  of 
humans (32). 
 
The importance of a well-preserved NK cell 
function in elderly is underscored by data showing that low 
NK cell activity is associated with development of 
infections and death due to infection in immunologically 
normal elderly subjects with an impaired performance 
status. The relative risk for the development of infection 
increased in accordance with the decrease in the NK cell 
activity and a low NK cell activity was associated with 
short survival due to infection. Furthermore, people 
aged > 85 year with low numbers of NK cells were 
reported to have three times the mortality risk in the first 
2 years of follow-up than those with high NK cell numbers. 
Other aspects of NK cell function, such as the secretion of 
chemokines or interferon-γ in response to interleukin (IL)-2 
are also decreased in the aged. Hence, high NK cytotoxicity 
associates with healthy Aging and longevity, whereas low 
NK cytotoxicity associates with increased morbidity and 
mortality due to infections, atherosclerosis, and poor 
response to influenza vaccination.  Together, these results 
support the notion that preserved NK cytotoxicity should be 
considered a biomarker of healthy Aging and longevity, 
whereas low NK cytotoxicity is a predictor of morbidity 
and mortality due to infections (29, 41-43). 
 
4. BIOMARKERS OF INFLAMMATION  
 
Aging is accompanied by chronic low-grade 
inflammation state, showed by a 2 to 4-fold increase in 
serum levels of inflammatory mediators which acts as 
predictors of mortality independent on pre-existing 
morbidity. This pro-inflammatory status of the elderly 
underlies biological mechanisms responsible for physical 
function decline, and inflammatory age-related diseases  
are initiated or worsened by systemic inflammation (44-
46). In fact, an inflammatory response appears to be the 
prevalent triggering mechanism driving tissue damage 
associated with different age-related diseases and the term 
"inflamm-Aging" has been coined to explain the 
underlining inflammatory changes common to most age-
associated diseases (44,45,47-49). It is mostly the 
consequence of the body ability to counteract and modulate 
the effects of a variety of stressors, which cause the 
accumulation of molecular and cellular scars. However, a 
wide range of different aetiological factors contributes to 
increased low-grade inflammatory activity in elderly 
including a decreased production of sex steroids, smoking, 
subclinical disorders such as atherosclerosis, asymptomatic 
bacteruria, a higher amount of fat as well as cellular 
senescence (49,50).  
 
However, there is a link among an individual 
exposure to past infection, levels of chronic inflammation 
and increased risk of heart attack, stroke, Alzheimer’s 
disease (AD), Parkinson’s disease, cancer, type-2 diabetes, 
sarcopenia, functional disability and high mortality risk. In 
addition, within individuals, C-reactive protein (CRP) 
levels are also correlated with the number of 
seropositivities to common pathogens, suggestive of 
infection history (44, 51-62). 
 
Tumor necrosis factor(TNF)-alfa is an 
independent prognostic marker for mortality in persons 
aged 100 years and in elderly nursing home patients 
detectable serum level of TNF- alfa  were associated with 
death within 13 months. Plasma levels of TNF-α are 
correlated linearly with Interleukin (IL)-6 and CRP reactive 
protein in centenarians, indicating an interrelated activation 
of the entire inflammatory cascade in the oldest old. High 
circulating levels of TNF- alfa and IL-6 as well as CRP 
have been related to CVD and frailty. Moreover, TNF- alfa 
has been linked to AD  and type 2 diabetes, and IL-6 has 
been demonstrated to be a strong predictor of mortality 
itself. Increased levels of CRP, IL-6 and TNF- alfa are 
associated with insulin resistance in elderly non-diabetic 
subjects and highly sensitive CRP levels are significant 
predictors of subsequent diabetes and metabolic syndrome 
as well as AD. The prospective InCHIANTI study 
demonstrated that high levels of IL-6, CRP and IL-1, are 
significantly associated with poor physical performance 
and muscle strength (60,63-78).  
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On the other hand, white blood cell count (WBC) 
is an important predictor of all-causes mortality in aged,  
mostly  CVD and a high leukocyte count may identify 
high-risk individuals who are not currently identified by 
traditional CVD factors (79,80). 
 
During normal Aging, the gradual loss of 
telomeric DNA in dividing somatic cells can contribute to 
replicative senescence, apoptosis, or neoplastic 
transformation. Hence, an association between telomere 
length and mortality in 143 normal unrelated individuals 
over the age of 60 years. Those with shorter telomeres in 
blood DNA had poorer survival, attributable in part to a  
higher mortality rate from heart disease  and a mortality 
rate from infectious disease. Telomere shortening of blood 
cells, likely due to increased rounds of replication 
depending on life-long immune-inflammatory stimuli, 
contributes to mortality in many age-related diseases. 
Hence, these results  suggest their possible role as 
biomarkers. However, unfortunately they have not been yet 
extensively confirmed (81). 
 
The majority of above described immune-
inflammatory aspects, that characterize the 
immunosenescence, are also detectable in extreme 
longevity, where a higher frequency of genetic markers 
associated with a reduced pro-inflammatory ability seems 
to counteract the onset of the main age-related disorders. 
Centenarians are quite capable of mounting effective 
inflammatory responses; however, inflammatory status, 
correlated to increasing risk of developing frailty and 
diseases, is compensated by the concomitant development 
of strong and effective anti-inflammatory responses (39, 
82,83).  
 
4.1.Oxidative stress  
The “free radical theory of Aging” has captivated 
the scientific attention as a possible biological explanation 
of the entire Aging process (84, 85). Oxidative stress has 
been linked to a variety of medical problems related to 
Aging, such as CVD, cancer, diabetes and AD (86, 87). 
Many in vitro markers of oxidative stress are available, but 
most are of limited value in vivo because they lack 
sensitivity and/or specificity or require invasive methods. 
Thus the results of studies investigating oxidative stress in 
human Aging are still controversial, and there are still 
limited and conflicting results available in the literature 
(88-91). 
 
There is considerable literature supporting a key 
role of oxidative stress in the clinical phenotype, with direct 
evidence of significant increases in oxidative DNA 
damage, protein oxidation and lipid peroxidation 
(86,87,92). Moreover, numerous studies have demonstrated 
that oxidative stress is increased in frail, institutionalised 
elderly people, and may lead to an accelerated Aging, while 
in free living elderly this increase is not always significant.  
 
An example of biomarkers of oxidative stress, in 
vivo, is the measure of lipid peroxidation, although 
producing contradictory results. Lipid oxidation not only 
causes membrane disruption, it also produces aldehydic 
species, such as malondialdehyde (MDA), able to 
perpetrate further damage by binding to and modifying 
proteins (93). MDA, though certainly not perfect, has 
widely performed as a biomarker to ascertain whether 
lipoperoxidation has taken place (93, 94) and it has been 
often utilized to evaluate human Aging. In vivo results in 
elderly are quite ambiguous. In numerous studies plasma 
MDA, evaluated by means of the thiobarbituric acid test, 
was significantly higher in healthy elderly, confirming the 
presence of increased lipoperoxidation in old age. 
Nevertheless, other studies in healthy older subjects, 
reported a biological antioxidant status similar to those of 
younger elderly subjects (95). 
 
Recently, isoprostanes (IsoPs), compounds that 
are produced in vivo by free radical-induced peroxidation 
of arachidonic acid, have been also proposed to assess 
oxidative stress status in vivo, but there are still few 
evidences of their consistency (96). The data from literature 
suggest that lipid peroxidation is a less sensitive marker of 
oxidative stress than protein oxidation (90). The most 
widely studied oxidative stress-induced modification to 
proteins is the formation of carbonyl derivatives. Carbonyl 
formation can occur through a variety of mechanisms 
including direct oxidation of certain amino-acid side chains 
and oxidation-induced peptide cleavage. Protein carbonyl 
level is a stable and generic signal of protein oxidative 
damage (97, 98). The importance of protein oxidation in 
Aging is supported by the observation that levels of 
oxidized proteins increase with animal age, but again in 
humans in vivo studies results are poor and uncertain. 
Although all organs and all proteins can potentially be 
modified by oxidative stress, certain tissues and specific 
protein targets may be especially sensitive. For example, 
recent studies have applied redox proteomic, a branch of 
proteomics that identifies oxidatively-modified proteins, to 
characterize specific proteins in brain Aging, and a number 
of proteins that are oxidatively modified in AD have been 
identified (99).  
 
Oxygen free radicals can induce a variety of 
damage to DNA, including DNA single and double strand 
breaks, base modifications and abasic sites (100). 8-
hydroxy-2-deoxyguanosine (8-OHdG) is by far the most 
studied oxidative DNA lesion and has gained much 
attention because of its mutagenic potential (101). The 
formation of 8-OHdG in leukocyte DNA and the excretion 
of 8- OHdG into urine have been frequently measured by 
high performance liquid chromatography or mass 
spectrometry to assess oxidative stress in humans. 
Compared with the determination of 8-OHdG in leukocyte 
DNA, the measurement of urinary 8-OHdG offers some 
advantages, because it is non-invasive, there is less 
production of artifacts during sample procedure, it better 
represent a marker of oxidative DNA damage and repair 
from all cells in the organism (102). Although some studies 
have identified an age-related increase of 8-OHdG in 
healthy volunteers (103), prospective study of oxidatively 
damaged DNA as a predictor of risk for age related 
pathologies is extremely difficult and few interesting 
results have been obtained to date. In addition, the 
accumulation of oxidation products several studies have 
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associated Aging with a progressive loss of antioxidant 
defence (104, 105).  
 
Reactive oxygen species (ROS) production is 
largely counteracted by an intricate antioxidant defence 
system that includes the enzymatic scavenger 
superoxidodismutase (SOD), catalase and glutathione 
peroxidise (GSH-Px). SOD speeds the conversion of 
superoxide to hydrogen peroxide, whereas catalase and 
glutathione peroxidise convert hydrogen peroxide to water. 
The most recently discovered SOD isoenzyme is the 
extracellular SOD (EC-SOD) that plays a primary role as 
main enzymatic scavenger of superoxide in the 
extracellular space (106). Numerous researches evaluated 
the impact of Aging process on EC-SOD activity, but the 
results are yet disparate. There are conflicting evidences 
about the effect of Aging on GSH-Px activity. In the 
French PAQUID study, there were no changes in GSH-Px 
with age (107). BELFAST study has shown a decline in 
GSH-Px in well free-living nonagenarians (95) and other 
studies have demonstrated the same in institutionalized old 
subjects (109). In a recent population-based study, 
cognitive decline was associated with lower activity of the 
protective selenium-dependent GSH-Px and a higher 
activity of Cu/Zn-SOD (110). 
 
In addition to these well characterized antioxidant 
enzymes a variety of other non-enzymatic, low molecular 
mass molecules are important in scavenging ROS. These 
include ascorbate, pyruvate, flavonoids, carotenoids, uric 
acid and perhaps most importantly, glutathione (GSH), an 
ubiquitous antioxidant which is present in millimolar 
concentrations within cells. GSH depletion can enhance 
oxidative stress, GSH level and the ratio between GSH and 
oxidized glutathione (GSSG)  is decreased in models of 
Aging and correction of low tissue glutathione increased 
longevity (109,110). Thus it has been speculated that 
glutathione status could be an indicator of health and 
functional age. In the BELFAST study GSH plasma levels 
were increased in nonagenarians compared to 
septo/octogenarians (95). It has been recently shown in 204 
volunteers with a broad age spectrum that blood GSH 
concentration declines with age (111). Another study, 
measuring cysteine/cystine and GSH/GSSG redox in 
plasma of 122 healthy individuals aged 19-85 years, 
showed a steady, linear increase in oxidative events 
throughout adult life and in particular that the capacity of 
the GSH antioxidant system is maintained until 45 years in 
healthy subjects and then declines rapidly (112).  
 
Recently, total plasma carotenoid levels have 
been suggested as a possible  health indicator in elderly 
populations. The 'Epidemiology of Vascular Aging' (EVA) 
study  have determined the association between baseline 
total plasma carotenoids and mortality. Low total plasma 
carotenoid levels were significantly associated with all-
cause mortality in men but not in women (113).  
 
In the context of stress response, eukaryotic cells 
are able to induce an evolutionarily highly conserved class 
of proteins known as heat shock proteins (HSPs) or stress 
proteins. A large body of evidence support a critical role 
for HSPs in cellular protection against ROS and a variety of 
other insults, including heat, hypoxia, ischemia, 
excitotoxicity, glucose deprivation, cancer, and Aging 
(114). The cellular protection of HSPs is attributed to their 
molecular chaperone function by facilitating nascent 
protein folding and refolding or degradation of abnormally 
folded proteins. Recently, the role of extracellular Hsp70 
(also referred to as serum Hsp70) begun to be addressed 
and it has been proposed as a potential biomarker of 
healthy Aging (115,116), easily measurable in the blood by 
the classical sandwich enzyme-linked immunosorbent 
assay (ELISA) (117).  Rea et al (118) examined serum 
Hsp70 in 60 individuals with ages ranging from 20 to 96 
years. They demonstrated a progressive decline in serum 
Hsp70 levels in older age groups. Similarly, Jin et al (119), 
in their study of 327 healthy male donors aged between 15 
and 50 years, demonstrated a decline in serum Hsp70 at 
older ages (between 30 and 50) although at younger ages, 
they noted a positive correlation with age. Terry et al., 
(120) in their cross-sectional study, have assessed serum 
Hsp70 levels from participants enrolled in either the New 
England Centenarian Study (93 centenarian offspring plus 
43  controls) or the Longevity Genes Project (87 
centenarians plus 83 controls),  showing that serum Hsp70 
levels are lower in those individuals that reach an advanced 
age. In addition, they have suggested that low serum Hsp70 
levels are associated with longevity independently on other 
covariates such as age, gender, race, income, alcohol, CVD, 
and a variety of other age-related diseases. It should be 
noted, however, that none of these studies, examined the 
changes in serum Hsp70 in the same individuals over time.  
 
5. CONCLUSIONS 
 
Aging is a complex process that negatively 
impacts the development of the different systems and their 
ability to function.  A long life in a healthy, vigorous, 
youthful body has always been one of humanity greatest 
dreams. During the last years, an increasing number of 
scientific meetings, articles, and books have been devoted 
to anti-Aging therapies. This subject, full of misleading, 
simplistic, or wrong ideas, is very popular among the 
general public, whose imagery has been fascinated by all 
possible tools  to delay Aging and to get immortality. 
Hence, the search for Aging biomarkers continues because 
such  biomarkers would have tremendous relevance to the 
current push to identify drugs that ameliorate the Aging 
processes. 
 
As discussed by Johnson (121), The American 
Federation for Aging Research has proposed the following 
criteria for a Biomarker of Aging:  
 
1. It must predict the rate of Aging, exactly telling where a 
person is in his/her total life span.  
2. It must monitor a basic process that underlies the Aging 
process rather than  the effects of disease. 
3. It must be able to be tested repeatedly without harming 
the person, as a blood test. 
4. It must be something that works in humans and in 
laboratory animals. Hence, it should be tested in laboratory 
animals before being validated in humans. 
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Table 1. Biomarkers of unsuccessful aging 
Unsuccessful Aging  Ref 
Memory T cells ↓ 14-16 
Effector T cells ↑  
T cell repertoire ↓  
IgG anti CMV ↑ 17,21-29 
DN B cells ↑ 40 
CRP ↑ 44,51-62 
TNF ↑ 60,63-78 
IL-6 ↑  
IL-1 ↑  
WBC ↑ 79,80 
Telomere length Short 81 
MDA ↑ 93-95 
8-OHdG ↓ 101-103 
Plasma carotenoids ↓ 113 
For the explanation see the text 
 
Table 2. Biomarkers of successful aging 
Successful Aging  Ref 
Naive T cells ↑ 16-20 
T cells function ↑  
NK function and number ↑ 29,41-43 
IgM ↑ 31-33,40 
Naive B cell ↑  
GSH-Px ↑ 106,110 
GSH ↑  
Serum HSP70 ↓ 115,118 
For the explanation see the text 
 
For over 15 years, the National Institute on Aging 
has supported research on biomarkers of Aging. While 
many important findings have developed, no biomarker has 
yet been identified” (http://www.infoaging.org). The 
general feeling of the Aging community is that biomarkers 
fulfilling all of the above criteria are unlikely to exist. 
Hence, we discussed some disease-related biomarkers 
(summarized in Table 1) as well as markers found in 
successful Aging  (summarized in Table 2) useful for a 
better understanding of Aging  and for the development of 
new strategies to counteract it essential for improving the 
quality of life of the elderly population. In fact, this kind of 
knowledge is useful to anti-Aging strategies aimed to slow 
Aging and to postpone death by preventing infectious 
diseases and delaying the onset of age-related diseases  (55, 
11, 122,123). 
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